Search | Clinical Trials Finder

Conditions: Leukemia, Lymphoma, Multiple Myeloma, Aplastic Anemia
Interventions: Umbilical Cord Blood After Myeloablative Conditioning, Umbilical Cord Blood After Reduced-Intensity Conditioning; Biological
Lead sponsor: Tufts Medical Center; Other
Eligibility: Up to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anemia of Chronic Kidney Disease
Interventions: vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 4 Months to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Anemia
Interventions: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 6
States / cities: Los Angeles, California • San Jose, California • Boston, Massachusetts + 3 more

Conditions: Myelodysplastic Syndromes
Interventions: gemtuzumab ozogamicin; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sickle Cell Disease
Interventions: SCD Group; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sickle Cell Disease, Kidney Injury, Kidney Diseases, Kidney Disease, Chronic
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year to 25 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Paroxysmal Nocturnal Hemoglobinuria
Interventions: Crovalimab, Eculizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Charlotte, North Carolina • Columbus, Ohio

Conditions: Sickle Cell Disease
Interventions: GBT021601; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Atlanta, Georgia

Conditions: Paroxysmal Nocturnal Hemoglobinuria
Interventions: Danicopan; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more

Conditions: Iron Deficiency Anemia
Interventions: Iron Supplement, multivitamin; Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 24 Weeks to 32 Weeks
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Blood Loss Anemia, Osteoarthritis, Hip
Interventions: Tranexamic acid, Placebo; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Iron Deficiency Anemia, Iron-deficiency
Interventions: 95% condensed proanthocyanidins from grape seed extract; Dietary Supplement
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Autoimmune Disease, Autoimmune Hemolytic Anemia, Thrombocytopenia
Interventions: Isolex 300i; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anemia
Interventions: BAY85-3934, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: alemtuzumab, therapeutic allogeneic lymphocytes, fludarabine phosphate, melphalan, tacrolimus, thiotepa, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Skin Ulcers, Sickle Cell Anemia
Interventions: Arginine Butyrate, Standard local care dressing; Drug · Other
Lead sponsor: Susan P. Perrine; Other
Eligibility: 16 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more

Conditions: AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), CMML
Interventions: AlloHeme; Diagnostic Test
Lead sponsor: CareDx; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Brisbane, California • San Francisco, California • St Louis, Missouri

Conditions: Sickle Cell Disease
Interventions: Evaluation of cognitive and pre-academic skills, Parent questionnaires; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 48 Months to 68 Months
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Restless Legs Syndrome (RLS)
Interventions: Injectafer® (Ferric Carboxymaltose - FCM), Placebo (Normal Saline); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Lemon Grove, California • Fort Myers, Florida • Orlando, Florida + 5 more

Conditions: Anemia of Chronic Kidney Disease
Interventions: Erythropoiesis-Stimulating Agent (ESA), Vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 18
States / cities: Montgomery, Alabama • Hartford, Connecticut • Middlebury, Connecticut + 9 more

Conditions: Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, Adult Myelodysplastic Syndrome, Adult Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Diffuse Large B-Cell Lymphoma, Childhood Myelodysplastic Syndrome, Childhood Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Mantle Cell Lymphoma, Plasma Cell Myeloma, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia, Waldenstrom Macroglobulinemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Sirolimus, Total-Body Irradiation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 4
States / cities: Denver, Colorado • Salt Lake City, Utah • Seattle, Washington

Conditions: G6PD Deficiency
Interventions: SD Biosensor G6PD Analyzer, Pointe Scientific Test Kit, HemoCue System; Diagnostic Test
Lead sponsor: PATH; Other
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sickle Cell Anemia
Interventions: Hydroxyurea; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 2 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: Birmingham, Alabama • Chicago, Illinois • New York, New York + 3 more

Conditions: Twin to Twin Transfusion Syndrome
Interventions: Curved KARL STORZ fetoscope, Conventional Scopes; Device
Lead sponsor: Jimmy Espinoza; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Phase II Study of Umbilical Cord Blood Transplantation

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)

Acute Kidney Injury in Patients With Sickle Cell Disease

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Trial Comparing Iron Supplementation Versus Routine Iron Intake in Very Low Birth Weight Infants

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

Multiple Daily Condensed Tannin Supplementation and Iron Bioavailability: The Tannin Dose Response Trial

Treatment of Autoimmune Thrombocytopenia (AITP)

Age and Gender Effects on the Pharmacokinetics of BAY85-3934

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers

Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)

Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Validation of Diagnostics to Identify Glucose-6-phosphate Dehydrogenase Activity in the US

Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia

The Efficacy of the KARL STORZ Curved Fetoscope and Straight Fetoscope for Laser Photocoagulation of Placental Anastomoses